bioAffinity Technologies, Inc. has received notification from the China National Intellectual Property Administration regarding the allowance of a patent application related to its noninvasive lung cancer diagnostic methods. This development is significant given China's substantial population of smokers, which contributes to the country's high rate of lung cancer. The patent, titled "System and Method for Determining Lung Health," involves the use of specific antibodies and the porphyrin TCPP to label cell populations in sputum, utilizing flow cytometry to detect lung cancer cells. This notification is part of bioAffinity's strategy to expand its proprietary diagnostic platform internationally.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。